{"product_id":"jxr-fertility-pestle-analysis","title":"Jinxin Fertility PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic pressures, and evolving healthcare technologies are reshaping Jinxin Fertility’s outlook—our concise PESTLE highlights the external forces that matter most and how they affect strategy and risk. Purchase the full analysis for an actionable, fully editable report ideal for investors, consultants, and executives seeking immediate insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina Pro-Natalist Policy Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFrom 2023–2025 China has rolled out aggressive pro-natalist measures, including provincial expansions of paid maternity leave and direct subsidies for assisted reproduction; pilot programs in 15 provinces reported a 20–30% increase in IVF consultations in 2024. Government funding increased fertility-treatment reimbursements by up to 50% in select regions, lowering out-of-pocket costs and boosting demand. For Jinxin Fertility, state incentives and greater insurance coverage create a clear policy-driven revenue tailwind as more couples seek assisted services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Tensions and Cross-Border Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing US-China friction elevates strategic risk for Jinxin Fertility’s California operations and its international referral programs, with US investment reviews of Chinese healthcare deals rising 45% from 2019–2024 under CFIUS-related scrutiny.\u003c\/p\u003e\n\u003cp\u003ePolitical concerns about data security and biological assets have prompted state-level audits and could impose additional compliance costs—estimates suggest US compliance upgrades can add 2–5% to operating expenses.\u003c\/p\u003e\n\u003cp\u003eManagement must navigate diplomatic and regulatory complexity to protect cross-border investments and lab collaborations from export controls, visa limits, and potential sanctions that disrupted 12% of comparable medical partnerships in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Insurance Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy end-2025, 18 Chinese provinces had added ART services to public medical insurance, expanding potential patient pool by an estimated 35–40% and lowering average out-of-pocket costs by roughly CNY 20,000 per cycle. This policy shift moves demand from private-pay to state-supported coverage, enabling Jinxin Fertility to capture higher volume—projected revenue uplift of 15–25% if market share holds. However, provinces often impose pricing caps (e.g., CNY 10,000–15,000 for standard IVF), pressuring margins on high-volume procedures. Jinxin must balance increased throughput with cost control and potential government reporting\/compliance requirements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Licensing Barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Chinese government enforces strict licensing for IVF and specialized fertility services; as of 2024 only licensed hospitals and select private chains meet national health commission criteria, keeping sector growth controlled.\u003c\/p\u003e\n\u003cp\u003eThese high entry barriers shield leaders like Jinxin Fertility—which reported RMB 1.2 billion revenue in 2023—from fragmented new entrants, preserving market share.\u003c\/p\u003e\n\u003cp\u003eJinxin must sustain compliance with evolving NHC standards to avoid license suspension or fines; regulatory breaches in 2022–24 saw penalties up to RMB 10 million across the industry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrict licensing limits entrants, favoring incumbents\u003c\/li\u003e\n\u003cli\u003eJinxin: RMB 1.2B revenue (2023), benefits from barriers\u003c\/li\u003e\n\u003cli\u003eNoncompliance risk: suspensions, fines up to ~RMB 10M (2022–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS Reproductive Rights Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFollowing legal volatility, state-level laws in 2025 continue to reshape fertility clinic operations; IVF is largely protected federally but 12 states have enacted or proposed personhood-related measures affecting embryo handling and storage.\u003c\/p\u003e\n\u003cp\u003eChanges in personhood statutes can force altered disposal protocols and increase compliance costs; estimated incremental legal and facility expenses for clinics range from $0.5M–$2M annually per large clinic in high-risk states.\u003c\/p\u003e\n\u003cp\u003eJinxin’s US assets require continuous legal monitoring and adaptive SOPs to manage litigation risk, potential patient flow shifts, and state-specific licensing requirements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 states with personhood measures (2025)\u003c\/li\u003e\n\u003cli\u003eEstimated $0.5M–$2M extra annual compliance per large clinic\u003c\/li\u003e\n\u003cli\u003eIVF largely protected federally but subject to state-level operational constraints\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy-driven ART boom could lift Jinxin revenue 15–25% amid rising compliance costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePro-natalist policies (2023–25) and provincial ART insurance expansion (18 provinces) drove 20–40% demand growth and could lift Jinxin revenues 15–25% (RMB 1.2B in 2023 baseline); licensing barriers protect incumbents but noncompliance fines reached ~RMB 10M (2022–24). US-China tensions and 12 US states' personhood measures raise cross-border compliance costs ($0.5M–$2M\/clinic).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 Revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProvincial ART coverage\u003c\/td\u003e\n\u003ctd\u003e18 provinces\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDemand uplift\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected revenue uplift\u003c\/td\u003e\n\u003ctd\u003e15–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNoncompliance fines\u003c\/td\u003e\n\u003ctd\u003e~RMB 10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS clinic extra costs\u003c\/td\u003e\n\u003ctd\u003e$0.5M–$2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces—Political, Economic, Social, Technological, Environmental, and Legal—specifically impact Jinxin Fertility, combining current regulatory and market data with industry trends to identify targeted risks and opportunities for strategic decision‑making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise PESTLE summary for Jinxin Fertility that’s visually segmented for quick interpretation, easily droppable into presentations, and editable for regional or business-line notes to streamline risk discussions and team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Disposable Income in Emerging Tiers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rise of China’s middle class in tier-2 and tier-3 cities expanded demand for premium fertility services, enlarging the TAM by an estimated 18–22% from 2019–2024; household healthcare spending grew ~9% CAGR (2019–2023), with fertility\/reproductive care a notable share. Jinxin has responded by opening clinics in 12 regional cities through 2024, targeting a projected regional revenue uplift of ~25% by 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Push Inflation in Medical Supplies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal cost-push inflation has raised prices for ART reagents, equipment and consumables by an estimated 8–12% in 2024–25, squeezing margins for Jinxin Fertility as lab supplies account for ~18% of variable costs.\u003c\/p\u003e\n\u003cp\u003eManaging these rising operational expenses while keeping patient fees competitive forces Jinxin to balance margin preservation with price sensitivity in a market where average IVF cycle prices rose ~6% in 2024.\u003c\/p\u003e\n\u003cp\u003eCentralized procurement and scale economies—consolidating purchases across clinics to negotiate discounts of 10–20%—are critical levers for protecting profit margins amid sustained input-price inflation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic Slowdown and Elective Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePeriodic cooling in China—GDP growth easing to 5.2% in 2024 from 8.1% in 2021—can make some consumers postpone high-cost elective fertility treatments; surveys in 2023 showed 27% delaying medical spending amid income uncertainty. While fertility is often essential, timing of cycles shifts with job instability and a 6–8% drop in urban household net wealth in parts of 2023–24. Jinxin’s tiered pricing and service mix across premium, mid and budget options (prices ranging from ~RMB 10k–120k) cushions demand volatility by retaining cost-sensitive clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs Jinxin Fertility operates heavily in China and the US, RMB\/USD volatility materially affects consolidated revenue translation and reported margins; in 2024 the RMB moved about 4.5% against the dollar, increasing FX translation variability for cross-border earnings.\u003c\/p\u003e\n\u003cp\u003eCurrency swings also raise the USD cost of US capital projects and imported medical equipment; a sustained 5% RMB depreciation versus 2023 would raise dollar-denominated capex by roughly the same proportion.\u003c\/p\u003e\n\u003cp\u003eJinxin mitigates exposure through strategic hedging, RMB-denominated revenue mixes, and localizing operating expenses in the US to reduce balance-sheet FX risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 RMB\/USD volatility ~4.5% year-on-year\u003c\/li\u003e\n\u003cli\u003ePotential ~5% capex uplift if RMB weakens 5%\u003c\/li\u003e\n\u003cli\u003eHedging and expense localization used to stabilize financials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Competition for Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy late 2025, demand for embryologists and fertility specialists pushed median specialist salaries up ~18% YoY in China’s tertiary clinics, with top-tier embryologists commanding CNY 600–900k annually; Jinxin must boost retention spending and match market rates to avoid poaching by rivals.\u003c\/p\u003e\n\u003cp\u003eRising human-capital expense is structural for specialized medical services, forcing sustained investment in compensation, training, and retention to secure clinical capability and protect service volumes and margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedian specialist pay +18% YoY (2025)\u003c\/li\u003e\n\u003cli\u003eTop embryologist pay CNY 600–900k\/year\u003c\/li\u003e\n\u003cli\u003eNeed higher retention spend, competitive packages, training\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargin squeeze amid RMB volatility and wage inflation despite 18–22% TAM growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic headwinds—slower GDP (5.2% in 2024), RMB\/USD volatility ~4.5% and 8–12% input inflation—compress margins despite 18–22% TAM growth in tier-2\/3 cities; centralized procurement, hedging and tiered pricing cushion impact while wage inflation (median specialist pay +18% YoY; top embryologists CNY 600–900k) raises operating costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina GDP 2024\u003c\/td\u003e\n\u003ctd\u003e5.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMB\/USD vol (2024)\u003c\/td\u003e\n\u003ctd\u003e~4.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput price rise (2024–25)\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTAM growth (2019–24)\u003c\/td\u003e\n\u003ctd\u003e18–22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian specialist pay YoY (2025)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eJinxin Fertility PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. This Jinxin Fertility PESTLE Analysis covers political, economic, social, technological, legal, and environmental factors with actionable insights and data-backed observations. The layout, content, and structure visible here are exactly what you’ll download immediately after buying. No placeholders—this is the final, professional file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751221997945,"sku":"jxr-fertility-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/jxr-fertility-pestle-analysis.png?v=1772229003","url":"https:\/\/growthsharematrix.com\/products\/jxr-fertility-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}